Viracta Therapeutics (VIRX) Earnings Date, Estimates & Call Transcripts $0.14 -0.01 (-4.70%) (As of 12:15 PM ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Viracta Therapeutics Latest Earnings SummaryLatest Q2 2024 Earnings DateAug. 14EstimatedActual EPS (Aug. 14) -$0.25 Beat By $0.10 Consensus EPS (Aug. 14) -$0.35 Viracta Therapeutics issued Q2 2024 earnings on August 14, 2024, reporting an EPS of -$0.25, which topped analysts' consensus estimates of -$0.35 by $0.10. With a trailing EPS of -$1.10, Viracta Therapeutics' earnings are expected to grow next year, from ($0.80) to ($0.36) per share. Get Viracta Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Viracta Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataVIRX Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.VIRX Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Behind the MarketsDylan Jovine's #1 Retirement Play for 2024Register: My First LIVE Event in 5 Years! On Tuesday, November 19th, I'm breaking my "no webinars" rule and going LIVE at 8:00pm Eastern. You won't want to miss this event. I'm releasing my No. 1 Retirement Play in 2024. It has nothing to do with regular stocks, options, cryptos or any investment fads.Click here now to register for "Our #1 Takeover Target for November" event. Viracta Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20242-$0.34-$0.25-$0.30Q2 20242-$0.35-$0.25-$0.30Q3 20242-$0.36-$0.21-$0.29Q4 20242-$0.37-$0.13-$0.25FY 20248($1.42)($0.84)($1.13) Viracta Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks8/14/2024Q2 2024-$0.35-$0.25+$0.10-$0.25--5/9/2024Q1 2024-$0.35-$0.23+$0.12-$0.23--3/7/2024Q4 2023-$0.30-$0.35 -$0.05-$0.35--11/9/2023Q3 2023-$0.33-$0.33--$0.33--8/14/2023Q2 2023-$0.30-$0.32 -$0.02-$0.32--5/8/2023Q1 2023-$0.31-$0.32 -$0.01-$0.32-- Get the Latest News and Ratings for VIRX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Viracta Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 3/13/2023Q4 2022-$0.40-$0.27+$0.13-$0.27-- Viracta Therapeutics Earnings - Frequently Asked Questions When did Viracta Therapeutics announce their last quarterly earnings? Viracta Therapeutics (NASDAQ:VIRX) last announced its quarterly earning data on Wednesday, August 14, 2024. Learn more on VIRX's earnings history. Did Viracta Therapeutics beat their earnings estimates last quarter? In the previous quarter, Viracta Therapeutics (NASDAQ:VIRX) reported ($0.25) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.35) by $0.10. Learn more on analysts' earnings estimate vs. VIRX's actual earnings. How much profit does Viracta Therapeutics generate each year? Viracta Therapeutics (NASDAQ:VIRX) has a recorded net income of -$51.06 million. VIRX has generated -$1.10 earnings per share over the last four quarters. What is Viracta Therapeutics's EPS forecast for next year? Viracta Therapeutics's earnings are expected to grow from ($0.80) per share to ($0.36) per share in the next year. ` More Earnings Resources from MarketBeat Related Companies LPCN Earnings Results GOVX Earnings Results TPST Earnings Results BTAI Earnings Results NAII Earnings Results CMMB Earnings Results RNXT Earnings Results GLYC Earnings Results ENLV Earnings Results LSTA Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Alibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of EarningsLam Research Proves Analysts Wrong with a Strong Earnings Report Dylan Jovine's #1 Retirement Play for 2024 (Ad)Register: My First LIVE Event in 5 Years! On Tuesday, November 19th, I'm breaking my "no webinars" rule and going LIVE at 8:00pm Eastern. You won't want to miss this event. I'm releasing my No. 1 Retirement Play in 2024. It has nothing to do with regular stocks, options, cryptos or any investment fads.Click here now to register for "Our #1 Takeover Target for November" event. This page (NASDAQ:VIRX) was last updated on 11/18/2024 by MarketBeat.com Staff From Our Partners5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredFREE investing Class TOMORROW + 2 FREE BonusesOver the last 37 years on Wall Street, I've developed a unique investing strategy that allows me to find stock...Unstoppable Prosperity | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredShocking footage from Bill Gates’ $100,000,000,000 AI BetIf you missed out on Nvidia, watch this video I just made.Brownstone Research | Sponsored🗓️ My First LIVE Event in 5 Years!Give us 60 minutes and we’ll show you how we’ve compressed 15 years of stock market gains into one day.Behind the Markets | SponsoredElon Musk’s $30 Billion Trump Bet Pays Off—What’s Next?Elon Musk bet big on Trump's victory, and that gamble has already added over $30 billion to his net worth in a...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viracta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viracta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
